A recent study by researchers at the University of Arizona Health Sciences suggests that a previously ineffective immunotherapy for prostate cancer could become viable when combined with a targeted treatment approach. Published in Cancer Immunology Research, the study highlights a method to enhance immune checkpoint inhibitors by inhibiting a key protein, PIM1 kinase, to improve immune response.

Tumor-associated macrophages (TAMs) are white blood cells that cancer hijacks to suppress immune attacks. The study found that PIM1 kinase, a protein known for promoting cancer cell survival and growth, plays a crucial role in enabling prostate cancer to evade immunotherapy. By blocking PIM1 kinase, researchers successfully reprogrammed macrophages to support, rather than suppress, the immune system’s ability to fight cancer.

Immune checkpoint inhibitors work by preventing cancer cells from shutting down T cells, the immune system’s primary cancer-fighting agents. While this therapy has been effective for various cancers, prostate cancer has remained resistant. The study found that inhibiting PIM1 kinase in combination with checkpoint inhibitors significantly reduced tumor growth in laboratory and animal models.

PIM inhibitors are already being tested in various cancer treatments, and researchers hope this discovery will lead to clinical trials at the University of Arizona Cancer Center. If successful, this approach could offer a breakthrough in prostate cancer treatment, helping more patients benefit from immunotherapy.

Source.